Novel Therapeutics in Soft Tissue Sarcoma.

Area of Science:

• Oncology
• Molecular Biology
• Pharmacology

Background:

• Soft tissue sarcomas (STS) are a rare and heterogeneous group of cancers.
• Significant progress has been made in understanding STS molecular characteristics and developing targeted treatments.

Purpose of the Study:

• To review recent advancements in molecular characterization and therapeutics for soft tissue sarcomas.
• To highlight novel agents approved by the FDA and investigational treatments for various STS subtypes.

Main Methods:

• Review of recent FDA approvals for novel agents in STS treatment.
• Summary of investigational therapies targeting specific molecular alterations and pathways in STS.
• Discussion of challenges and future directions in STS drug development.

Main Results:

• Several novel agents, including tyrosine kinase inhibitors (avapritinib, ripretinib), immune checkpoint inhibitors (atezolizumab), and others (nirogacestat, larotrectinib, entrectinib, nab-sirolimus, tazemetostat), have gained FDA approval for specific STS subtypes.
• Investigational treatments like MDM2 and CDK4/6 inhibitors, further immune checkpoint inhibitors, and PARP inhibitors show promise.
• Accelerated approval was granted for autologous T-cell therapy (afami-cel) in synovial sarcoma.

Conclusions:

• Despite challenges posed by rarity and molecular heterogeneity, significant therapeutic progress is being made in soft tissue sarcomas.
• Future progress hinges on a deeper understanding of STS biology, development of novel compounds for challenging targets (e.g., Proteolysis Targeting Chimeras - PROTACs), innovative clinical trial designs, and industry-academia collaboration.